Emerald Health Pharmaceuticals to Present Preclinical Data at the 29th Annual Symposium of the International Cannabinoid Research Society
June 19, 2019 09:26 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, June 19, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, will present preclinical data...
Emerald Health Pharmaceuticals to Participate at the Neurotech Investing & Partnering Conference
May 15, 2019 08:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, May 15, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, will participate in a panel...
Emerald Health Pharmaceuticals Receives U.S. Drug Enforcement Administration Determination that the Active Ingredient in its Lead Product Candidate is not a Controlled Substance
April 17, 2019 08:00 ET
|
Emerald Health Pharmaceuticals
Development of EHP-101, a clinical-stage cannabidiol (CBD) derivative, simplified by DEA determination SAN DIEGO, CA, April 17, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc....
Emerald Health Pharmaceuticals’ Cannabinoid-Derived Drug Candidate, EHP-102, Shows Potential Disease-Modifying Activity in Huntington’s Disease Models
March 21, 2019 07:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, March 21, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, announced today that newly...
Emerald Health Pharmaceuticals’ Cannabinoid-Derived Drug Candidate, EHP-101, Shows a Unique Mechanism of Action in Systemic Sclerosis Model, Indicating Key Differences Compared to Ajulemic Acid
March 19, 2019 13:14 ET
|
Emerald Health Pharmaceuticals
Biochemical Pharmacology publication describes the unique multi-target mechanism of action of EHP-101 with the potential to be beneficial in systemic sclerosis, a complex disease with no current...
Emerald Health Pharmaceuticals Appoints Lisa Sanford as Chief Financial Officer
March 12, 2019 08:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, March 12, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, has appointed Lisa Sanford as...
Emerald Health Pharmaceuticals Appoints Joachim P.H. Schupp, M.D., Dr. med. as Chief Medical Officer
January 23, 2019 07:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, has appointed Joachim Schupp,...
Emerald Health Pharmaceuticals to Present at the 2nd Annual Sach’s Neuroscience Innovation Forum and the 11th Annual Biotech Showcase 2019
January 03, 2019 07:00 ET
|
Emerald Health Pharmaceuticals
San Diego, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, announced today that CEO, Dr. Jim...
Emerald Health Pharmaceuticals Forms Scientific Advisory Board
December 18, 2018 11:00 ET
|
Emerald Health Pharmaceuticals
Initial appointments include global experts in cannabinoid and drug discovery science SAN DIEGO, CA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage...
Emerald Health Pharmaceuticals will Present at the International Cannabinoid-Derived Pharmaceuticals Summit
December 04, 2018 07:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, today announced that Dr. Jim...